Advanced

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, Bengt; Gedde-Dahl, Tobias; Markevarn, Berit; Remes, Kari; Stentoft, Jesper; Almqvist, Anders; Bjoreman, Mats; Flogegard, Max; Koskenvesa, Perttu and Lindblom, Anders, et al. (2011) In Blood 118(12). p.3228-3235
Abstract
Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34... (More)
Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (< 12-week MMR rate 67%, > 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent. (Blood. 2011;118(12):3228-3235) (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
118
issue
12
pages
3228 - 3235
publisher
American Society of Hematology
external identifiers
  • wos:000295120900009
  • scopus:80053130415
ISSN
1528-0020
DOI
10.1182/blood-2011-02-336685
language
English
LU publication?
yes
id
11ae7b43-2405-47aa-8312-ebed89fd3a37 (old id 2179995)
date added to LUP
2011-11-01 07:53:32
date last changed
2017-11-12 03:09:38
@article{11ae7b43-2405-47aa-8312-ebed89fd3a37,
  abstract     = {Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (&lt; 12-week MMR rate 67%, &gt; 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent. (Blood. 2011;118(12):3228-3235)},
  author       = {Simonsson, Bengt and Gedde-Dahl, Tobias and Markevarn, Berit and Remes, Kari and Stentoft, Jesper and Almqvist, Anders and Bjoreman, Mats and Flogegard, Max and Koskenvesa, Perttu and Lindblom, Anders and Malm, Claes and Mustjoki, Satu and Myhr-Eriksson, Kristina and Ohm, Lotta and Rasanen, Anu and Sinisalo, Marjatta and Sjalander, Anders and Stromberg, Ulla and Bjerrum, Ole Weiss and Ehrencrona, Hans and Gruber, Franz and Kairisto, Veli and Olsson, Karin and Sandin, Fredrik and Nagler, Arnon and Nielsen, Johan Lanng and Hjorth-Hansen, Henrik and Porkka, Kimmo},
  issn         = {1528-0020},
  language     = {eng},
  number       = {12},
  pages        = {3228--3235},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia},
  url          = {http://dx.doi.org/10.1182/blood-2011-02-336685},
  volume       = {118},
  year         = {2011},
}